Lung Cancer News

Use of an artificial intelligence program detected lung nodules up to 1 year before their detection by radiologists, researchers reported at the virtual European Respiratory Society International Congress.

Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile.

Patients with early-stage non-small cell lung cancer who received best supportive care vs. atezolizumab after adjuvant chemotherapy had a higher relapse rate, but relapse patterns appeared similar between the groups, study results showed.

Most patients with lung cancer — including those receiving active therapy — produced neutralizing antibodies to COVID-19 after vaccination, according to study results.

Trastuzumab deruxtecan demonstrated strong antitumor activity among patients with previously treated HER2-mutated non-small cell lung cancer, according to results of a multicenter phase 2 trial presented during the virtual ESMO Congress.

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results.

The FDA approved mobocertinib for treatment of certain patients with non-small cell lung cancer.

Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, according to study results.

First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results.

Older patients with late-stage non-small cell lung cancer appeared to benefit from immunotherapy, according to results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.